The Swing trader: Top High-Volatility Stocks v.2 (TA) AI trading robot has demonstrated its prowess once again, delivering impressive gains of +4.43% while trading AMGN (Amgen) over the previous week. This article will delve into the recent earnings results of AMGN and analyze the potential implications for traders.
Analyzing Earnings Results:
AMGN's latest earnings report, released on April 27, showcased the company's strong performance, surpassing expectations with earnings per share (EPS) of $3.98 compared to the estimated $3.82. This positive surprise indicates the company's ability to generate robust profits and highlights its potential for growth.
Market Capitalization:
With 41.92K shares outstanding, AMGN's current market capitalization stands at an impressive $122.14 billion. This figure reflects the market's valuation of the company based on its outstanding shares and demonstrates AMGN's substantial presence in the pharmaceutical industry.
Technical Analysis:
Aside from the encouraging earnings results, technical indicators also suggest a potential shift in AMGN's stock trend. On June 2, 2023, the Relative Strength Index (RSI) Oscillator for AMGN moved out of oversold territory. This development indicates that the stock may be transitioning from a downward trend to an upward trend, presenting an opportunity for traders.
To further analyze this shift, the A.I.dvisor examined 32 instances when the RSI indicator left oversold territory. In 20 out of those 32 cases, the stock price moved higher. This statistical observation implies that the probability of AMGN moving higher after leaving oversold territory is approximately 62%.
Implications for Traders:
Considering the positive earnings report, with AMGN surpassing EPS estimates, combined with the technical analysis indicating a potential shift in the stock's trend, traders may view this as an opportune moment. The positive earnings results and the RSI indicator's movement out of oversold territory provide a favorable backdrop for considering investment in AMGN, either through buying the stock or call options.
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on AMGN as a result. In 46 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 191 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 46%.
AMGN moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Aroon Indicator for AMGN entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.342) is normal, around the industry mean (19.199). P/E Ratio (25.971) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.025) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of human therapeutic products based on cellular biology
Industry PharmaceuticalsMajor